Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Insulin Makers May Be First In Crosshairs Of DeGette Rx Pricing Investigation

Jan 17 2019

• By Derrick Gingery

Diabetes

Related Content

Medicare IPI Model Could Import Benefit Of Biosimilar Competition, Azar Suggests

Jan 16 2019

House Oversight Drug Pricing Hearings Will Begin With Expert, Patient Witnesses

Jan 14 2019

Trulicity DTC Ads Reference Lilly Website For List Price, Cost Sharing Info

Jan 11 2019

Democrats’ Drug Pricing Bills Echo Trump Ideas But Broad Republican Support Unlikely

Jan 11 2019

Will CBO Score CREATE Momentum For Generic Bill's Passage?

Sep 19 2018

Drug Pricing Legislation Appears Nowhere In Sight Following Senate Hearing

Oct 18 2017

'Immediate' Steps To Lower Drug Prices: The HHS Action Plan

May 14 2018

US FDA's Gottlieb Shuts The Door On Exclusivity For 'Transition' Biologics

Dec 11 2018

When Drugs Become Biologics: US FDA Guidances Explain 'Transition Provisions'

Dec 11 2018

Scrutiny Of EpiPen Pricing Invited By Mylan Lobbying, Congressman Says

Sep 22 2016

Related Companies

Eli Lilly and Company

Novo Nordisk A/S

Sanofi

Additional Topics

United States Pricing Debate Regulation FDA Biosimilars Metabolic Disorders BioPharmaceutical

More from Pricing Debate

More from Market Access

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.